

## What is ICOS?

The International CardiOncology Society  
([www.cardioncology.com](http://www.cardioncology.com))

- It is a group of interested and committed medical providers that hope to eliminate cardiac disease as a barrier to cancer treatment



#### THE SOCIETY

About us  
Constitution  
Said about us

FUND RAISING

#### MEMBERS

Founders  
Honorary Members  
Members  
Corresponding Members  
APPLY FOR MEMBERSHIP

#### CARDIONCOLOGY

Research  
Activity  
Background Articles  
Spotlight  
Ask the expert  
CARDIOTOXICITY REGISTER

#### LEGALE

Ask the lawyer

#### EVENTS

Cardiology and Oncology Partnership 2010  
Cardioncology 2009

#### CONTACTS



CARDIOTOXICITY  
REGISTER



#### CARDIONCOLOGY CONGRESS

MILAN 2009

CONGRESS PRESENTATIONS



CARDIOLOGY AND ONCOLOGY PARTNERSHIP  
IV ANNUAL INTERNATIONAL SYMPOSIUM  
Cardiology & Oncology  
partnership  
NASHVILLE 2010


HIGHLIGHTED PROCEEDINGS

#### CARDIONCOLOGY

Daniela Cardinale MD, PhD  
CARDIOLOGY UNIT, IEO.  
CARDIONCOLOGY



ASK THE EXPERT



A Special Issue of Progress in Cardiovascular Diseases:

#### War on Cancer Produces Collateral Damage to the Heart

This issue of Progress in Cardiovascular Disease was inspired by the very successful third International Symposium of the Cardiology Oncology Partnership, which was held in September 2009 in Milan, Italy. This meeting marked the inauguration of the International Cardioncology Society, an international society responding to the need for cooperation between these medical disciplines.

"The recent recognition of the frequent collateral damage of the heart from many of the newer chemotherapeutic agents, as well as the classic anthracyclines, and the importance of this to management of the cancer, should spur the acquisition of cardiac outcomes data and ultimately trigger the development of specific evidence-based practice guidelines to keep the heart from interfering with the war on cancer," commented Dr. Mann and Dr. Krone.

#### ONCOLOGY

Giuseppe Curigliano MD,  
PhD  
ONCOLOGY UNIT, IEO



SPOTLIGHT

NEWS & VIEWS FROM LITERATURE

**In heart we trust!**

The International Cardioncology Society (ICOS) was constituted January 2009 by Doctor Carlo Cipolla, European Institute of Oncology, Milano, Italy, accordingly to Doctor Daniel Lenihan, MD Anderson Cancer Center, Houston, Texas, USA. [Read more . . .](#)

## BOARD OF DIRECTORS

	AMERICAN BRANCH	EUROPEAN BRANCH
PRESIDENT	DANIEL LENIHAN	CARLO CIPOLLA
VICE PRESIDENT	CHARLIE PORTER	DANIELA CARDINALE
SCIENTIFIC SECRETARY	AARIF KHAKOO	GIUSEPPE CURIGLIANO
SCIENTIFIC COMMITTEE	LOUIS CONSTINE RON KRONE BONNIE KY APOSTOLIA TSIMBERIDOU	FABIO CICERI TOMMASO DE PAS AARON GOLDBIRSCH PIERGIUSEPPE PELICCI MARIA TERESA SANDRI THOMAS SUTER
EDUCATION/GUIDELINE COMMITTEE	JOSEPH CARVER DEBRA FRIEDMAN	ADRIANA ALBINI ALESSANDRO COLOMBO
IN CHARGE FOR ICOS IN ASIA	GOURI SHANKAR BHATTACHARYYA	
LEGAL ASSISTANCE		FRANCO DEL CURTO
TREASURER		FLAVIO PIROLA
WEBSITE		ANNA EGGERTZ
FUND RAISING		NATALIA POZZI

<b>From the Scientist Perspective, Many Mechanisms for Cell Survival and Repair are Common Between the Heart and Cancer Cells</b> Douglas B. Sawyer, MD, PhD	5-8
<b>Thrombosis in Cancer Patients: What are the treatments and the challenges?</b> Agnes Lee, MD, MSc, FRCPC	8-13
<b>Cardiac Biomarkers and Preclinical Detection of Cardiotoxicity</b> Daniela Cardinale, MD, PhD	13-18
<b>Common Terminology Criteria for Adverse Events and the Cardiovascular System</b> Scot C. Remick, MD	18-20
<b>Cardiac Issues In Cancer Patients: Are we responding appropriately?</b> Ronald M. Witteles, MD	20-24
<b>Molecular Basis of Cardiotoxicity May Lead to Cardiovascular Drug Development</b> Aarif Y. Khakoo, MD, MBA	25-28
<b>PREDICT Trial: Prospective Point of Care Cardiac Biomarkers to Detect Cardiotoxicity</b> Daniel J. Lenihan, MD	28-31
<b>Neuregulin In Heart Failure: An Upstream Effect of ERB2 Signaling</b> Carrie A. Geisberg, MD	32-35
<b>Multicenter Registry for CV Events During Cancer Therapy</b> Bonnie Ky, MD, MSCE	36-39
<b>Amyloidosis: A Disease all Cardiologists Should Know About</b> David C. Seldin, MD, PhD	39-45
<b>Hypertension and Cardiac Issues From the Perspective of the Practitioner</b> Michael J. Fisch, MD, MPH	45-48
<b>Is Preventing and Optimally Treating Heart Failure In Cancer Patients a Reasonable Goal?</b> JoAnn A. Lindenfeld, MD	48-51

*Taking survival to heart.®*



Cardiology & Oncology Partnership  
IV Annual International Symposium

October 7-9, 2010  
Nashville, Tennessee

# Recent Publications and accomplishments

- Progress in Cardiovascular Diseases (Vol. 53, No. 2, Sept/Oct 2010, Elsevier)
- Heart Failure Clinics (July 2011 issue)
- Many manuscripts in high profile journals in the past 2 years (>10)
- Initiated 2 new multicenter studies
- Multicenter Registry for Cardiotoxicity is in progress
- Many presentations and focused sessions at international meetings

# ICOS goals:

- Define cardiovascular risk assessment
- Integrate necessary sophisticated cardiac testing during oncology research into reported findings
- Explore optimal screening techniques being mindful of practical issues
- Standardize definitions for cardiac-related events during chemotherapy
- Contribute to the creation of an international database
- Promoting prevention of heart failure and other major cardiac events during cancer treatment
- Active management of preexisting cardiac disease by a cardiologist can promote the most effective cancer therapy
- Understanding expected clinical outcomes for each discipline to have shared decision making

Flash forward to 2025:

All the cardiologists, oncologists, and primary MDs of the world will have learned that for the optimal care of cancer patients, they enjoy working together.